
Sign up to save your podcasts
Or


Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.
By American Society of Gene & Cell Therapy4.9
1616 ratings
Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.

38,513 Listeners

30,808 Listeners

43,633 Listeners

38,798 Listeners

3,438 Listeners

767 Listeners

827 Listeners

6,421 Listeners

9,554 Listeners

322 Listeners

6,563 Listeners

34 Listeners

21 Listeners

38 Listeners

50 Listeners